Skip to content 
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts. more
| Dec '25 | ||||||
|---|---|---|---|---|---|---|
| Total Revenue | - | [{"date":"2025-12-31","value":"-","profit":true}] | ||||
| Cost of Revenue | - | [{"date":"2025-12-31","value":"-","profit":true}] | ||||
| Gross Profit | - | [{"date":"2025-12-31","value":"-","profit":true}] | ||||
| Gross Margin | - | [{"date":"2025-12-31","value":"-","profit":true}] | ||||
| Operating Expenses | 158.34M | [{"date":"2025-12-31","value":100,"profit":true}] | ||||
| Operating Income | (158.34M) | [{"date":"2025-12-31","value":-15834000000,"profit":false}] | ||||
| Total Non-Operating Income/Expense | 9.38M | [{"date":"2025-12-31","value":100,"profit":true}] | ||||
| Pre-Tax Income | (148.96M) | [{"date":"2025-12-31","value":-14895500000,"profit":false}] | ||||
| Income Taxes | - | [{"date":"2025-12-31","value":"-","profit":true}] | ||||
| Income After Taxes | - | [{"date":"2025-12-31","value":"-","profit":true}] | ||||
| Income From Continuous Operations | (148.96M) | [{"date":"2025-12-31","value":-14895500000,"profit":false}] | ||||
| Income From Discontinued Operations | - | [{"date":"2025-12-31","value":"-","profit":true}] | ||||
| Net Income | (148.96M) | [{"date":"2025-12-31","value":-14895500000,"profit":false}] | ||||
| EPS (Diluted) | - | [{"date":"2025-12-31","value":"-","profit":true}] | ||||
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| KLRA | |
|---|---|
| ROA (LTM) | -22.73% |
| ROE (LTM) | -36.90% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| KLRA | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.00 |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Kailera Therapeutics, Inc. Common Stock (KLRA) share price today is $24.26
Yes, Indians can buy shares of Kailera Therapeutics, Inc. Common Stock (KLRA) on Vested. To buy
Yes, you can purchase fractional shares of Kailera Therapeutics, Inc. Common Stock (KLRA) via the Vested app. You can start investing in Kailera Therapeutics, Inc. Common Stock (KLRA) with a minimum investment of $1.
You can invest in shares of Kailera Therapeutics, Inc. Common Stock (KLRA) via Vested in three simple steps:
The 52-week high price of Kailera Therapeutics, Inc. Common Stock (KLRA) is $28.23. The 52-week low price of Kailera Therapeutics, Inc. Common Stock (KLRA) is $16.
The price-to-earnings (P/E) ratio of Kailera Therapeutics, Inc. Common Stock (KLRA) is
The price-to-book (P/B) ratio of Kailera Therapeutics, Inc. Common Stock (KLRA) is 0.00
The dividend yield of Kailera Therapeutics, Inc. Common Stock (KLRA) is 0.00%
The market capitalization of Kailera Therapeutics, Inc. Common Stock (KLRA) is $3.25B
The stock symbol (or ticker) of Kailera Therapeutics, Inc. Common Stock is KLRA
Consider the share price of Kailera Therapeutics, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Kailera Therapeutics, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Kailera Therapeutics, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Kailera Therapeutics, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Kailera Therapeutics, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Kailera Therapeutics, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
